Breaking World Pharma News
Merz to create three independent, customer-focused healthcare businesses to drive growth
Merz, a global, diversified healthcare company, has announced plans for a new business structure that will enable the company to better address customer and patient needs, shorten innovation cycles and capitalize on new market opportunities. Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced 'viǝ-trīs). Protein could offer therapeutic target for pancreatic cancer
Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
4 - 5 February 2020, London, UK.SMi presents Europe's leading 14th annual Parallel Trade conference, taking place in London. As the only B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.
Bayer invests USD 50 Million in eGenesis Series B financing round
eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. The pathway to Parkinson's takes a surprising twist
FDA approves first therapy to treat patients with rare blood disorder
Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept-aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. RNA Therapeutics Conference and Focus Day
19 - 20 February 2020, London, UK.The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.
AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development
AstraZeneca announced three large-scale initiatives to build on the Company's long-standing commitment to China and advance global research and development (R&D) for innovative new medicines. The announcements made at the 2nd annual China International Import Expo (CIIE) in Shanghai include the creation of a new Global R&D Centre and an artificial intelligence (AI) Innovation Centre, both in Shanghai, and the creation of a first-of-its-kind Healthcare Industrial Fund with China International Capital Corporation Limited (CICC). More Pharma News ...
Business & Industry
- Merz to create three independent, customer-focused healthcare businesses to drive growth
- Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
- Bayer invests USD 50 Million in eGenesis Series B financing round
- AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development
- Abbott announces discovery of new strain of HIV, keeping global health community a step ahead of the virus
Research & Development
- A step closer to cancer precision medicine
- Protein could offer therapeutic target for pancreatic cancer
- The pathway to Parkinson's takes a surprising twist
- Unique case of disease resistance reveals possible Alzheimer's treatment
- Cannabis could help alleviate depression and suicidality among people with PTSD
- Synthetic phages with programmable specificity
- Researchers find new signaling systems in human cells
Conferences & Events
- Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
- RNA Therapeutics Conference and Focus Day
- CPhI Worldwide announces the winners of the 16th Pharma Awards
- CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023
- SMi's 9th Annual Pharmaceutical Microbiology UK Conference
- 'FDA should withdraw ANDAs', and 'new technologies could bring massive improvements in efficiency' if implemented correctly
- SMi's 9th Annual Orphan Drugs & Rare Diseases Conference
Regulatory Affairs
- FDA approves first therapy to treat patients with rare blood disorder
- Digital submission of adverse event reports for investigational new drug applications
- First vaccine to protect against Ebola
- FDA approves new treatment for patients with migraine
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases